|

Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients

RECRUITINGSponsored by Amgen
Actively Recruiting
SponsorAmgen
Started2025-08-11
Est. completion2026-02-28
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07143513

Summary

The primary objective of this study is to characterize the safety profile of sotorasib.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Adult (≥ 18 years) as of the index date.
* KRAS p.G12C-mutated locally advanced or metastatic NSCLC.
* Received at least 1 dose of sotorasib.
* Receipt of at least 1 prior systemic therapy before use of sotorasib.
* Obtained ICF, if required.

Exclusion Criteria:

* Documentation of being a non-Chinese ethnicity.

Conditions3

CancerLung CancerNon Small Cell Lung Cancer

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.